Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Gitlin

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Journal of Medical Economics|January 13, 2011
Study of the incremental cost and clinical burden of hip fractures in postmenopausal women in the United KingdomLia Gutiérrez, Neil Roskell, Jordi Castellsague, et al.
Bone|June 12, 2012
Clinical burden and incremental cost of fractures in postmenopausal women in the United KingdomLia Gutiérrez, Neil Roskell, Jordi Castellsague, et al.
American Journal of Nephrology|November 24, 2021
Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release CalcifediolGeorge Fadda, Michael J Germain, Varshasb Broumand, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 22, 2011
Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patientsKirsten L Johansen, Fredric O Finkelstein, Dennis A Revicki, et al.
Clinical Therapeutics|March 4, 2014
Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013George N Coritsidis, Gregory A Maglinte, Anjali Acharya, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|December 9, 2010
Dialysis patients treated with Epoetin α show improved exercise tolerance and physical function: A new analysis of the Canadian Erythropoietin Study Group trialNorman Muirhead, Paul A Keown, David N Churchill, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|August 24, 2013
TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patientsAdam E Gaweda, Premila Bhat, Gregory A Maglinte, et al.
Leukemia & Lymphoma|May 21, 2021
Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trialsM Lia Palomba, Monika Parisi Jun, James Lymp, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 18, 2008
Identifying best practices in dialysis care: results of cognitive interviews and a national survey of dialysis providersAmar A Desai, Roger Bolus, Allen Nissenson, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|March 30, 2010
Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trialPaul A Keown, David N Churchill, Melanie Poulin-Costello, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Journal of Medical Economics|January 13, 2011
Study of the incremental cost and clinical burden of hip fractures in postmenopausal women in the United KingdomLia Gutiérrez, Neil Roskell, Jordi Castellsague, et al.
Bone|June 12, 2012
Clinical burden and incremental cost of fractures in postmenopausal women in the United KingdomLia Gutiérrez, Neil Roskell, Jordi Castellsague, et al.
American Journal of Nephrology|November 24, 2021
Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release CalcifediolGeorge Fadda, Michael J Germain, Varshasb Broumand, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 22, 2011
Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patientsKirsten L Johansen, Fredric O Finkelstein, Dennis A Revicki, et al.
Clinical Therapeutics|March 4, 2014
Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013George N Coritsidis, Gregory A Maglinte, Anjali Acharya, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|December 9, 2010
Dialysis patients treated with Epoetin α show improved exercise tolerance and physical function: A new analysis of the Canadian Erythropoietin Study Group trialNorman Muirhead, Paul A Keown, David N Churchill, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|August 24, 2013
TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patientsAdam E Gaweda, Premila Bhat, Gregory A Maglinte, et al.
Leukemia & Lymphoma|May 21, 2021
Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trialsM Lia Palomba, Monika Parisi Jun, James Lymp, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 18, 2008
Identifying best practices in dialysis care: results of cognitive interviews and a national survey of dialysis providersAmar A Desai, Roger Bolus, Allen Nissenson, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|March 30, 2010
Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trialPaul A Keown, David N Churchill, Melanie Poulin-Costello, et al.
Pageof 6